Comparative Pharmacology
Head-to-head clinical analysis: MIRCETTE versus TRI MILI.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MIRCETTE versus TRI MILI.
MIRCETTE vs TRI-MILI
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination of ethinyl estradiol and desogestrel; estrogen and progestin inhibit gonadotropin release, suppressing ovulation and altering cervical mucus and endometrial receptivity.
TRI-MILI is a combination of norethindrone (a progestin) and ethinyl estradiol (an estrogen). Norethindrone suppresses gonadotropin release, inhibiting ovulation. Ethinyl estradiol stabilizes the endometrium and potentiates the progestational effects.
One tablet daily for 21 days, followed by 7 placebo tablets. Each active tablet contains 0.015 mg ethinyl estradiol and 2 mg chlormadinone acetate. Route: oral.
For mild-to-moderate hypertension: 1 tablet (containing triamterene 50 mg and hydrochlorothiazide 25 mg) orally once daily. May increase to 2 tablets daily if needed. Maximum dose: 4 tablets daily.
None Documented
None Documented
Desogestrel active metabolite etonogestrel: 21-24 hours; ethinyl estradiol: 12-14 hours
Terminal elimination half-life is 6-9 hours in adults with normal renal function, allowing twice-daily dosing; prolonged in renal impairment.
Urine (50-60% as metabolites, <10% unchanged), feces (30-40% as metabolites)
Renal excretion of unchanged drug accounts for 60-80% of elimination; biliary/fecal excretion accounts for 15-25%; remainder metabolized.
Category C
Category C
Oral Contraceptive
Oral Contraceptive